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The Hedgehog pathway plays important roles in embryonic development and oncogenesis, but how it affects
metabolism is less clear. D’Amico et al. (2015) now demonstrate that the Hedgehog pathway regulates trans-
lation of ornithine decarboxylase, thereby enhancing polyamine biosynthesis and cell proliferation in neural
precursor cells and in brain tumors.The Hedgehog (Hh) pathway is crucial for
regulating tissue patterning and growth
during development. In the developing
cerebellum, Hh signaling drives massive
proliferation of cerebellar granule cell
precursors. Aberrant activation of Hh
signaling is a frequent cause of medullo-
blastoma, a malignant childhood brain tu-
mor that is thought to originate from these
granule cell precursors. Effective small-
molecule inhibitors have been developed
to target Smoothened (Smo), the key pos-
itive regulator of the pathway, and these
have shown clear benefits in clinical trials
for medulloblastoma (Gajjar et al., 2013).
But clinical success is often transient,
as tumor cells can rapidly develop thera-
peutic resistance following treatment
(Robinson et al., 2015). Several different
mechanisms of resistance have been re-
ported, including secondary mutations in
Smo that reduce drug binding (Yauch
et al., 2009), activation or amplification
of the pathway transcription factor Gli2
(Buonamici et al., 2010), mutations in the
negative regulator Sufu (Kool et al.,
2014), and activation of RAS/MAPK onco-
genic pathway bypassing Hh pathway de-
pendency (Zhao et al., 2015). Thus, the
complexity of the Hh pathway allows
multiple mechanisms to bypass Smo inhi-
bition, indicating a clear need for new
strategies to meet the challenge of drug
resistance.
The paper by Canettieri and colleagues
in this issue of Developmental Cell
(D’Amico et al., 2015) sheds light on a
promising therapeutic strategy that tar-
gets polyamine metabolism and may be
effective in treating the Shh subgroup in
medulloblastoma, including tumors that
are resistant to Smo inhibitors. Studies
from the 1980s had shown that some me-
dulloblastomas exhibit high levels of poly-amines (Scalabrino et al., 1982). Here,
D’Amico et al. demonstrate that high
levels of polyamines are characteristic of
the Shh subgroup and are important for
tumor growth.
Polyamines are essential intracellular
substrates required for fundamental bio-
logical processes such as cell growth,
proliferation, and differentiation. The
metabolic biosynthesis, catabolism, and
transport of polyamines are therefore
tightly regulated. A rate-limiting step of
polyamine synthesis involves the enzyme
ornithine decarboxylase (ODC). Surpris-
ingly, D’Amico et al. observed that Hh
stimulation increases ODC protein levels
without affecting the mRNA. These data
suggest that Hh activation regulates
translation or degradation of ODC and
thereby affects intracellular metabolic ac-
tivity (Figure 1).
Loss of the tumor suppressor Patched
(Ptch) often occurs in medulloblastoma
and leads to Hh pathway activation. The
authors show that loss of Ptch also in-
creases polyamines and ODC protein
levels. Similarly, pathway activation by li-
gands of Ptch or of Smo increase poly-
amines and ODC levels. However,
when the authors examined another Hh
pathway component, Sufu, the results
were surprising. Although loss of Sufu
confers Hh pathway activation and
resistance to Smo inhibitors (Taylor
et al., 2002), knockdown of Sufu does
not increase ODC levels or polyamine
synthesis.
To resolve these puzzling and seem-
ingly contradictory findings, the authors
asked whether Sufu might exert tumor-
promoting activity by altering polyamine
biosynthesis, in addition to its well-known
tumor-suppressing activity (Taylor et al.,
2002). Indeed, they found that Sufu playsDevelopmental Cella role in the regulation of ODC translation.
Translation of ODC is known to be regu-
lated by the RNA/DNA binding protein
CNBP. In a series of reporter assays
and immunoprecipitation experiments,
D’Amico et al. demonstrated that CNBP
is a regulator of ODC translation. Impor-
tantly, the authors report that Sufu binds
CNBP and thereby inhibits CNBP protea-
somal degradation. Indeed, knockdown
of CNBP reduces ODC protein and poly-
amine levels, replicating the effect of
Sufu loss. The authors therefore conclude
that Sufu plays a role in cell metabolism
by binding and stabilizing CNBP, thus
preventing its ubiquitination and protea-
somal degradation.
Another surprising twist emerged when
D’Amico et al. tried to unravel the
mechanisms of Hh-dependent CNBP
activation. They identified an evolution-
arily conserved AMPK-consensus site in
CNBP and found that this phosphoryla-
tion site is critical in Hh-dependent
regulation of CNBP activity. A threonine-
to-alanine substitution at the critical
AMPK phosphorylation site prevents the
ability of Hh agonists to stimulate ODC
translation or increase polyamine levels.
Importantly, the phosphomimetic mutant
of CNBP exerts the opposite effect, as it
increases ODC levels even in the absence
of stimulation.
Canettieri and colleagues go on to
examine the potential clinical relevance
of these new mechanisms for medullo-
blastoma biology. They find that ODC,
CNBP, and polyamines are all strongly
elevated in SHH-subgroup medulloblas-
tomas. In a model of Shh-subgroup me-
dulloblastoma derived from Ptch mice,
the authors demonstrate that genetic
ablation of CNBP or pharmacological
targeting of ODC by a small-molecule35, October 12, 2015 ª2015 Elsevier Inc. 1
Figure 1. A Non-canonical Branch of Hh Signaling Regulating Polyamine Metabolism in
Normal and Cancer Cells
Loss of Ptch or stimulation by Smo agonist SAG triggers phosphorylation of the translational regulator
CNBP by AMPK, enhancing its stability by promoting association with Sufu. Activated CNBP increases the
translation of ODC, a key enzyme involved in polyamine biosynthesis. Increased polyamine levels are
associated with tumor growth. Sufu is required to stabilize CNBP, because loss of Sufu results in
degradation of CNBP and a reduction in the levels of ODC and polyamines.
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Previewsinhibitor, Difuoromethylornithine (DFMO),
decreases tumor cell proliferation both
in vitro and in vivo. Consistent with previ-
ous reports showing that CNBP is a major
regulator of the MYC gene as well as a
regulator of ODC (Michelotti et al., 1995),
D’Amico et al. show that polyamines are
also elevated in tumors that belong tome-
dulloblastoma group 3, which are charac-
terized by high levels of Myc. Because
DFMO is already being tested in clinical
trials for another childhood tumor, neuro-
blastoma, and has a good safety profile in
children, therapy with DFMO may be a
potential treatment for both SHH-sub-
group and group 3 medulloblastomas.2 Developmental Cell 35, October 12, 2015 ªAltogether, this new paper reports
several interesting findings that may
have a profound impact on our under-
standing of how metabolism is controlled
by developmental signaling pathways.
First, it establishes a link between poly-
amine metabolism and Hh signaling in
normal and cancer cells. Second, it offers
new mechanistic insight of how ODC, the
gatekeeper enzyme in polyamine meta-
bolism, is regulated by Hh pathway com-
ponents. Third, findings from this work
have therapeutic implications, as target-
ing polyamine metabolism may represent
an alternative option to treating medullo-
blastomas and offers new hope for tu-2015 Elsevier Inc.mors resistant to Smo inhibitors. Finally,
this paper highlights the need for further
studies to address the role of the Shh
pathway in post-transcriptional regulation
and in cellular metabolism.REFERENCES
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